CA
NZ
UK
AU
IND
US
Geron Corp's (NASDAQ: GERN) financial results reveal an earnings per share (EPS) of $-0.02 for the quarter ended June 30, 2026, slightly lagging behind the consensus estimate of $-0.01. This marks a challenging period for the biopharmaceutical company, particularly as it grapples with soaring …
Haemonetics Corp (NYSE: HAE) reported $339 million in revenue for the first quarter of fiscal 2027, demonstrating a 5.6% rise from the previous year. This solid performance is key as it signifies the company’s successful execution of its growth strategies, particularly in the plasma …
Harrow, Inc. (NASDAQ: HROW) will acquire global rights to the TYRVAYA nasal spray for $30 million, with additional milestone payments totaling up to $70 million based on annual sales thresholds. This transaction represents a significant strategic move for the company, enhancing its existing dry …
Eli Lilly’s rapid ascent in the obesity treatment market is underscored by nearly $27.7 billion in sales from its injectable GLP-1 drugs, significantly widening its gap with Novo Nordisk, which now lags behind by more than $10 billion. This expansion reflects a strong market …
Enovis CORP (NYSE: ENOV) unveiled its financial results for the second quarter ending on July 3, 2026, reporting net sales of $583 million, a 3% increase from the same quarter last year. The company's strong performance was bolstered by an 8% rise in its …
This strategic move is expected to bolster Ensysce's operational capabilities and growth in the competitive biotechnology environment.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported impressive financial results for the second quarter, achieving a revenue of $67.5 million. This figure marks a substantial increase of 31.7% compared to $51.3 million in the same quarter last year. This strong performance underscores Establishment Labs’ …
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced a net loss of approximately $35 million for the second quarter, indicating a significant increase from the $17.7 million net loss reported during the same period last year. This translated to a net loss per diluted share …
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) reported a quarterly EPS of $-0.81 for the period ending June 30, 2026, beating the $-0.83 consensus estimate. This positive earnings surprise highlights the company’s ability to manage costs effectively as it continues to invest in its clinical pipeline. …
Delcath Systems, Inc. (NASDAQ: DCTH) has raised its 2026 revenue guidance, projecting a total range of $104 million to $108 million, up 4% from prior estimates. This increase underscores the company's revenue growth momentum driven by the successful market adoption of its innovative HEPZATO …
Please wait processing your request...